New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs

Chinese Journal of Cancer

Volumn 32, Issue 5, 2013, Pages 233-241

  Beckman, Robert A ^a,b   Chen, Cong ^c  

^a DAIICHI SANKYO INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adaptive clinical trials; Evidence based approach; Predictive biomarkers

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BUDGET; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EFFECT SIZE; EQUIPOISE; EVIDENCE BASED MEDICINE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; IN VITRO STUDY; MATHEMATICAL ANALYSIS; MEDICAL DECISION MAKING; MEDICAL INFORMATION; ONCOLOGY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE TRANSITION; POWER ANALYSIS; PRACTICE GUIDELINE; PREDICTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

CLINICAL TRIALS AS TOPIC; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGRAM DEVELOPMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84877250356     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10248     Document Type: Article

References (30)

1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-H ER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 1999,17:2639-2648.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344:783-792.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004,30:1497-1500.
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004,101:13306-13311.
5. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008,26:1626-1634.
6. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 2006,66:3992-3995.
7. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-lin e treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol, 2008,26 Suppl 15:4000.
8. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-lin e treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008: 26 Suppl 15:2.
9. Yan L, Beckman RA. Pharmacogenetics and pharmaco-genomics in oncology therapeutic antibody development. Biotechniques, 2005,39:565-568.
10. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol, 2010,28:698-704.
11. Dalton WS, Friend, SH. Cancer biomarkers-an invitation to the table. Science, 2006,312:1165-1168.
12. Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov, 2011,10: 735-749.
13. Ratain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res, 2007,13:6545-6548.
14. Orloff J, Douglas F, Pineiro J. et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009; 8: 949-957.
15. Beckman RA. Efficiency of carcinogenesis: in the mutator phenotype inevitable? Semin Cancer Biol, 2010,20:340-352.
16. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res, 2008,68:3551-3557.
17. Beckman RA, Loeb LA. Genetic instability in cancer: theory and experiment. Semin Cancer Biol, 2005,15:423-435.
18. Chen C, Beckman RA. Optimal cost-effective Go-No Go decisions in late stage oncology drug development. Stat Biopharm Res, 2009,1:159-169.
19. Chen C, Beckman RA. Optimal cost-e ffective Phase II proof of concept and associated Go-No Go decisions. J Biopharm Stat, 2009,1:424-436.
20. Chen C, Sun L, Chih C. Evaluation of early efficacy endpoints for proof-of-concept Trials. J Biopharm Stat, 2013,23:413-424.
21. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst, 2009,101:1446-1452.
22. Dahle-Smith A, Petty RD. Developing predictive biomarkers in oncology: how can we achieve consistent success? In: Treatment Strategies-O ncology. London, UK: The Cambridge Research Centre, 2010:47-54.
23. Freidlin B, McShane L, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst, 2010,102:152-160.
24. Tang PA, Bentsen SM, Chen EX, et al. Surrogate endpoints for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-lin e chemotherapy. J Clin Oncol, 2007,25: 4562-4568.
25. Maheswaren S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med, 2008,359:366-377.
26. Mueller C, Edmiston KH, Carpenter C et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One, 2011,6:e23780.
27. Freidlin B, Simon RM. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res, 2005,11:7872-7878.
28. Simon RM. The use of genomics in clinical trial design. Clin Cancer Res, 2008,14:5984-5993.
29. Chen C, Beckman RA. Hypothesis testing in a confirmatory Phase III trial with a possible subset effect. Stat Biopharm Res, 2009,1:431-440.
30. Chen C, Sun L. On quantification of PFS effect for accelerated approval of oncology drugs, Stat Biopharm Res, 2011,3:434-444.